Table 1.
List of Oncolytic viruses delivering angiostatic gene therapy discussed in this paper
| OV NAME | THERAPEUTIC GENE | VIRUS TYPE | OV MUTATION | IN VIVO CANCER MODEL USED (EFFICACY +/−) | REF. |
|---|---|---|---|---|---|
| VEGF Targeting OV: | |||||
| ZD55-sflt-1 | sFlt-1 | Ad | E1B-55kDa deleted | Colorectal (+) | [31] |
| Ad-ΔB7-shVEGF | shRNA-VEGF | Ad | E1A mutated and ΔE1B | Glioma (+) | [33] |
| AdΔB7-KOX | F435-KOX | Ad | E1A mutated and ΔE1B | Glioma (+) | [34] |
| MMP Targeting OV: | |||||
| AdΔ24TIMP3 | TIMP3 | Ad | 24 b.p. deletion of E1A gene. | Glioma (−) | [45] |
| rQT3 | TIMP3 | HSV-1 | ΔICP34.5, and ΔICP6 | MPNST | [46] |
| Endostatin-Angiostatin Targeting OV: | |||||
| HSV-Endo | Endostatin | HSV-1 | ΔICP6 | Colon Carcinoma (+) | |
| AE618 | Endostatin- Angiostatin fusion Pr. | HSV-1 | ΔICP34.5, and ΔICP6 | Lung Cancer (+) | [58] |
| CNHK200-mE | Endostatin | Ad | E1B55kDa deleted | Hepatocellular carcinoma (+) | [60] |
| CNHK500-mE | Mouse Endostatin | Ad | hTERT controlled E1A, and Hypoxia regulated E1B. | Nasopharyngeal tumor (+) | [61] |
| Platelet Growth Factor Targeting OV: | |||||
| bG47Δ-PF4 | Platelet Factor-4 | HSV-1 | ΔICP34.5, ΔICP6, and ΔICP47 | Glioma (+) Malignant Peripheral Nerve Sheath Tumors (+) |
[65] |
| Fibroblast Growth Factor Targeting OV: | |||||
| bG47Δ-dnFGFR | dn Fibroblast growth factor | HSV-1 | ΔICP34.5−/−, ΔICP6, and ΔICP47 | Glioma (+) Malignant Peripheral Nerve Sheath Tumors (+) |
[72] |
| Interleukin 8 Targeting OV: | |||||
| Ad-ΔB7-U6shIL8 | shRNA-IL-8 | Ad | E1A mutated and ΔE1B | Liver Cancer (+) and Non small cell lung cancer (+) Pulmonary metastasis of breast (+) |
[76] |
Abbreviations: VEGF: Vascular Endothelial growth factor; sflt-1: soluble VEGF receptor flt-1; Ad: Adenovirus; sh-VEGF: small hairpin targeting VEGF; TIMP3: Tissue inhibitor of metalloproteinases; HSV-1: Herpes Simplex virus, dnFGFR: dominant negative Fibroblast growth factor receptor; shIL8: small hairpin targeting IL8.